BioPharm Systems Named to the 2010 Inc. 500:5000 List of Fastest-Growing Companies in the U.S.
BioPharm Systems announced that it has been named to Inc. magazine's list of the fastest-growing private companies in the United States for 2010. The Inc. 500|5000 ranks companies by overall revenue growth over a three-year period. BioPharm Systems was recognized for its 60 percent three-year growth rate.
"We are honored to be named among the many other prestigious companies in America," said Alex Sefanov, president and CEO of BioPharm Systems. "BioPharm has been growing at a consistent rate for many years. Our team continues to develop and provide new solutions in order to meet our clients' needs. This past year we launched a Siebel Clinical Trial Management System (CTMS) accelerator called ASCEND, and it has been generating a lot of interest due to its robust features, cost-effectiveness, and fast implementation process. We also have developed several other solutions, including Accel-Transfer, which is a tool that extracts, transforms, and loads data from one safety application into another.
BioPharm Systems, an Oracle Gold Partner specializing in Oracle Health Sciences' suite of clinical and safety applications, opened an office in the United Kingdom earlier this year.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
